Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer’s Drug

Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. Roche and AbbVie have clinical-stage drugs taking a similar approach to Alzheimer’s. The post Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer’s Drug appeared first on MedCity News.

Read More

Trump’s Transparent Hospital Pricing Pays Off for Industry — But Not So Much for Patients

“We’re going to post that, all the prices for everything,” Health and Human Services Secretary Robert F. Kennedy Jr. declared at a recent event held by the conservative Heritage Foundation in Washington. It’s a bold-sounding promise, and a familiar one; politicians from both parties have been repeating it for years now. Both Trump administrations — and the Biden administration in between — have taken whacks at making medical prices more accessible,…

Read More